A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic modelCraig H. Moskowitz, Joachim Yahalom, Stephen D. Nimer et al.|Blood|2001Cited by 427
Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's LymphomaCraig H. Moskowitz, Andrew D. Zelenetz, Joseph R. Bertino et al.|Journal of Clinical Oncology|1999Cited by 303
Randomized Controlled Trial of a Video Decision Support Tool for Cardiopulmonary Resuscitation Decision Making in Advanced CancerAngelo E. Volandes, Jennifer S. Temel, April F. Eichler et al.|Journal of Clinical Oncology|2012Cited by 171
Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphomaEunice S. Wang, Ariela Noy, David J. Straus et al.|Cancer|2003Cited by 151
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignanciesRobert Stuver, Santosha A. Vardhana, Gunjan L. Shah et al.|Cancer Cell|2022Cited by 88